U.S. Oil and Gas Stock News

Oklo (NYSE:OKLO) has entered a binding agreement with Meta Platforms to develop a 1.2 GW advanced nuclear campus dedicated to powering AI data centers. The partnership was highlighted at the 2026 World Economic Forum, where it drew high profile endorsements and wider attention to advanced nuclear technology. The deal positions small modular reactors as a potential power source for energy intensive AI infrastructure, attracting interest from institutions and policymakers. For investors...

Appian (APPN) recently announced a new Enterprise Agreement with the US Army, enabling up to US$500 million of software and cloud purchases over 10 years, alongside conditional authorization for its Appian Defense Cloud. See our latest analysis for Appian. The US Army agreement and recent appointment of AI-focused executive David Link to the board arrive at a time when Appian’s share price is US$30.06, with recent momentum mixed. A 7 day share price return of 5.03% contrasts with a 30 day...

First BanCorp (NYSE:FBP) has announced an 11% increase in its quarterly cash dividend. The change reflects the bank's current financial position and focus on returning cash to shareholders. This dividend adjustment is a material event for income focused investors tracking the stock. First BanCorp, a financial services company operating under the NYSE:FBP ticker, is closely watched by investors who care about income and capital stability. Dividend moves often draw attention because they...

Recent investor letters spotlighted Medpace Holdings (MEDP) after quarterly results exceeded expectations, with accelerated growth, a strong balance sheet, solid free cash flow, and sizable share repurchases at what investors viewed as attractive valuation levels. See our latest analysis for Medpace Holdings. The share price has consolidated around US$602.06 after a 2.38% 1 day share price return and a 6.08% 30 day share price return, while the 1 year total shareholder return of 71.84% and 5...

Wondering whether National Bank Holdings is genuinely good value or just fairly priced at current levels? This article walks through what the numbers say and how that stacks up against different ways to think about valuation. Over the short term, the stock has had a mixed run, with a 1.4% decline over the last 7 days, a 3.9% gain over 30 days, and a 6.4% return year to date, while the 1 year return sits at a 2.5% decline and the 5 year return at 34.8%. These moves sit alongside broader...

If you are wondering whether Ardelyx shares still offer value at around US$7.80, you are not alone. The recent price action has put the stock firmly on many watchlists. The share price sits at US$7.80 after returns of 15.6% over 7 days, 35.9% over 30 days, 26.8% year to date, 42.6% over 1 year and a very large gain over 3 years, with 12.1% over 5 years also adding context. Recent headlines around Ardelyx have focused on its position in the pharmaceuticals and biotech space and ongoing...

FFB Bancorp (FFBB) just wrapped up FY 2025 with fourth quarter revenue of US$19.4 million and basic EPS of US$1.08, setting the tone for how the full year is being assessed. Over recent quarters, revenue has moved from US$26.6 million in Q4 2024 to US$27.3 million in Q1 2025, US$24.2 million in Q2 2025 and US$22.8 million in Q3 2025, while quarterly EPS shifted from US$3.06 to US$2.56, US$1.95 and US$2.07 across the same stretch. Taken together with the latest trailing 12 month totals, these...

If you are wondering whether Dover's current share price lines up with its fundamentals, this article will walk through what the numbers are actually saying about value. Dover shares last closed at US$207.70, with returns of 0.5% over 7 days, 3.8% over 30 days, 6.1% year to date, 7.2% over 1 year, 50.3% over 3 years and 88.4% over 5 years, which can change how investors think about both upside potential and risk. Recent attention on Dover has been shaped by ongoing coverage of its role in...

The options market has turned unusually active around UP Fintech Holding (TIGR), as traders pile into call contracts and implied volatility climbs ahead of the company’s expected March 18 earnings release. See our latest analysis for UP Fintech Holding. That options activity comes after a mixed stretch for the stock, with a 1-day share price return of 1.37% at US$8.87 contrasting with a 90-day share price decline of 16.16%, while the 1-year total shareholder return of 33.99% and 3-year total...

If you are looking at Lithia Motors and wondering whether the recent share price gives you a fair entry, this article walks through what the current market price might be implying about value. The stock last closed at US$322.60, with returns of a 2.8% decline over 7 days, 6.3% decline over 30 days, 2.9% decline year to date and 8.7% decline over 1 year, set against a 30.8% gain over 3 years and 0.9% decline over 5 years. Recent coverage of Lithia Motors has focused on its position in the US...

If you are wondering whether DTE Energy is fairly priced or offering value right now, it helps to start by looking at how the market has treated the stock over different time frames. DTE Energy shares last closed at US$135.53, with returns of 0.0% over the past 7 days, 5.0% over 30 days, 4.0% year to date, 15.1% over 1 year, 31.6% over 3 years, and 57.1% over 5 years. Recent news flow around DTE Energy has focused on its role as a regulated utility and its ongoing capital investment plans...

Elanco Animal Health (NYSE:ELAN) has secured USDA approval for Befrena, a new product in its portfolio. The company has also received conditional FDA approval for Credelio Quattro, expanding its parasiticide offerings. Elanco is gaining traction in corporate veterinary channels, deepening its access to high-volume clinic groups. The company reports an ability to raise prices on core products with limited pushback from customers. Elanco Animal Health focuses on medicines and solutions for...

United Bankshares (NasdaqGS:UBSI) reported record earnings for 2025, supported by its acquisition of Piedmont Bancorp. The company completed the integration of Piedmont Bancorp, adding to its banking footprint and customer base. United Bankshares also finished a substantial share repurchase program, signaling a focus on returning capital to shareholders. United Bankshares operates as a regional banking group, providing lending, deposit, and related financial services to consumers and...

Paychex (NasdaqGS:PAYX) has appointed J. Michael Hansen, former Cintas CFO, to its Board of Directors as an independent director. The move expands the Paychex board and brings additional financial and leadership experience from a veteran executive in related industries. For investors watching Paychex at a current share price of $106.19, the board expansion arrives after a 26.0% decline over the past year and a 7.0% decline over the past 30 days. Over longer periods, the stock shows a 36.0%...

If you are wondering whether Alexandria Real Estate Equities is attractively priced right now, starting with a clear view of its valuation can help you frame that decision. The share price recently closed at US$57.16, with a 17.6% gain over 30 days, a 16.7% return year to date, but a 40.4% decline over 1 year that sits alongside 57.7% and 58.6% declines over 3 and 5 years. These moves sit against a backdrop of ongoing interest in listed real estate and changing sentiment toward specialized...

Lockheed Martin, PG&E Corporation, Salesforce and Wells Fargo recently launched EMBERPOINT LLC, a joint venture that applies artificial intelligence, autonomous systems and integrated command-and-control tools to help first responders detect, prevent and combat catastrophic wildfires. A key feature of EMBERPOINT is that agencies and utilities can access advanced wildfire-mitigation technology without bearing development costs, potentially broadening adoption of these systems across...

CorMedix overview and recent share performance CorMedix (CRMD) has drawn investor attention after a sharp pullback over the past month, with the share price down about 38% and roughly 30% lower over the past 3 months. That recent weakness comes despite a 1 day return of 6.74% and a 14.45% move over the past week. This may prompt some investors to reassess how the current price compares with the company’s fundamentals. See our latest analysis for CorMedix. Looking beyond the recent bounce,...

Peoples Bancorp of North Carolina (PEBK) just closed out FY 2025 with fourth quarter revenue of US$24.6 million and EPS of US$1.25, alongside trailing 12 month revenue of US$89.1 million and EPS of US$3.74 that reflects 21.3% earnings growth over the past year. Over recent periods, the company has seen quarterly revenue move from US$21.1 million in Q4 2024 to US$24.6 million in Q4 2025, while quarterly EPS shifted from US$0.67 to US$1.25. This sets up a story where improving margins and a...

KBRA recently assigned preliminary credit ratings to 56 classes of mortgage-backed notes from PMT Loan Trust 2026-CNF1, a prime RMBS transaction backed by 576 agency-eligible, conforming mortgage loans sponsored by PennyMac Corp., an indirect wholly owned subsidiary of PennyMac Mortgage Investment Trust. This fresh securitization highlights PennyMac Mortgage Investment Trust’s continued use of mortgage-backed markets to finance conforming, general QM loans and potentially broaden its...

U.S. Gold Corp recently advanced its CK Gold Project in Wyoming toward a Definitive Feasibility Study after securing US$31,000,000 in financing, while benefiting from record-high gold prices that enhance project economics and the perceived value of its Nevada and Idaho exploration assets. An interesting angle is how stronger gold prices can make mine-construction financing more attainable, potentially accelerating timelines for turning U.S.-based mineral resources into producing...

Sarepta Therapeutics (NasdaqGS:SRPT) reported positive 3 year data from the EMBARK Phase 3 study of Elevidys gene therapy in Duchenne muscular dystrophy. The results show sustained functional benefits in ambulatory Duchenne patients over 3 years with a manageable safety profile. No new safety issues were identified in the 3 year readout, addressing prior concerns around long term efficacy and safety. Sarepta Therapeutics focuses on genetic medicines for rare neuromuscular diseases, and...

If you are wondering whether BridgeBio Pharma's share price still makes sense after a strong run, this article focuses on what the numbers say about value rather than the excitement around the stock. The stock trades at US$77.81, with returns of 2.0% over the past week, 2.7% over the past month, a slight year to date decline of 0.5%, a 112.2% return over the past year, a very large 3 year gain that is around 7x, and a 35.5% return over 5 years. Recent news around BridgeBio has centered on...

Piper Sandler Companies recently reported that over the past two years it has delivered strong annual growth in revenue, earnings per share, and tangible book value per share, all pointing to improved profitability and capital strength. What stands out is that earnings per share expansion has far outpaced revenue growth, implying meaningful efficiency gains and better operating leverage across the business. We’ll now examine how this outsized earnings growth, relative to revenue, may...

Chewy (NYSE:CHWY) has announced the retirement of its Chief Technology Officer, Satish Mehta. The leadership transition affects oversight of Chewy's technology platforms and product development efforts. Stakeholders are assessing what this change could mean for the company's future technology priorities. Chewy, trading at $31.43, has seen its share price under pressure, with a 7 day return of a 6.8% decline and a 1 year return of a 19.3% decline. Over 3 years, the stock has recorded a 27.3%...